Indivior PLC SUPN
Indivior PLC (Nasdaq: SUPN) is a drug developer. Its lead program is marketed. Its next catalyst on record is SUBUTEX divestiture: Transaction close and regulatory approval of marketing authorization transfer (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SUBUTEX divestiture — Transaction close and regulatory approval of marketing authorization transfer (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SUBLOCADE | Opioid use disorder (OUD) | biologic-other | Approved |
| SUBOXONE Film | Opioid dependence | small molecule | Approved |
| SUBOXONE Tablet | Opioid dependence | small molecule | Approved |
| SUBUTEX Tablet | Opioid dependence | small molecule | Approved |
Recent results and decisions
- Apr 30, 2026missed Phase 2 proof-of-concept study of INDV-2000 in OUD did not meet its primary endpoint of no treatment failure; Indivior will not advance it internally.
INDV-2000 did not meet the primary endpoint of “no treatment failure.”
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.